<DOC>
	<DOC>NCT00555724</DOC>
	<brief_summary>Phase 1, open-labeled, dose escalation safety and tolerability study for the treatment of subjects with relapsed or refractory solid tumors.</brief_summary>
	<brief_title>Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Age 18 years or older at the time of informed consent Relapsed or refractory solid tumors following standard therapy. ECOG Performance Status 0 or 1. History of insulindependent diabetes, type 2 diabetes, or hemoglobin A1c &gt;6% at screening. History of myocardial infarction within 12 months prior to Day 1 or chronic heart failure. Known central nervous system or brain metastases. Prior antiIGF1R therapy of any kind. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>refractory</keyword>
	<keyword>solid tumor</keyword>
</DOC>